Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung Cancer

耶鲁 SPORE 肺癌 (YSILC)：肺癌的生物学和个性化治疗

• 批准号: 10203850
• 负责人: Roy S Herbst
• 金额: $ 200.37万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-26 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10203850
• 关键词: Address; Adoption; Animal Disease Models; Area; Award; Biochemical; Biochemistry; Bioinformatics; Biological; Biological Assay; Biology; Biometry; Biopsy; Blood; Brain; Brain Neoplasms; Cancer Biology; Cancer Etiology; Cancer Hospital; Cancer Patient; Cell surface; Cells; Cessation of life; Clinical; Clinical Research; Clinical Trials; Comprehensive Cancer Center; Connecticut; DNA Sequence Alteration; Development; Diagnosis; Disease; Drug resistance; Environment; Epidermal Growth Factor Receptor; Epigenetic Process; Frequencies; Funding; Gene Expression Alteration; Generations; Genetic; Genomics; Goals; Grant; Human; Human Cell Line; Immune; Immune response; Immunologics; Immunooncology; Immunosuppressive Agents; Immunotherapy; In Vitro; Liquid substance; Lung Adenocarcinoma; Malignant Neoplasms; Malignant neoplasm of lung; Metastatic Neoplasm to the Central Nervous System; Metastatic malignant neoplasm to brain; Molecular; Morbidity - disease rate; Mutation; Myeloid Cells; Neoplasm Metastasis; Neuraxis; Non-Small-Cell Lung Carcinoma; Outcome; Pathology; Pathway interactions; Patients; Pharmacology; Physicians; Play; Pre-Clinical Model; Production; Proteins; Protocols documentation; Recording of previous events; Refractory Disease; Reproduction spores; Research; Research Personnel; Resistance; Resistance development; Resource Sharing; Role; Sampling; Scientist; Selection for Treatments; Solid Neoplasm; Source; Speed; Structure; T-Lymphocyte; Testing; Translating; Tyrosine Kinase Inhibitor; United States; Yale Cancer Center; anticancer research; base; bench to bedside; biomarker development; biomarker evaluation; cancer cell; cancer drug resistance; cancer therapy; career; clinical application; clinical care; clinically actionable; combat; design; effectiveness evaluation; improved; in vivo; innovation; macrophage; mortality; mouse model; mutant; next generation; novel; novel therapeutic intervention; novel therapeutics; outreach; personalized medicine; prevent; programmed cell death ligand 1; programs; prospective; resistance mechanism; sialic acid binding Ig-like lectin; targeted treatment; translational cancer research; translational research program; translational scientist; translational study; tumor; tumor microenvironment; tumor progression

YALE SPORE IN LUNG CANCER (YSILC) OVERALL SUMMARY The Biology and Personalized Treatment of Primary and Metastatic Lung Cancer: The YSILC unites translational scientists spanning diverse areas of cancer research to converge on addressing the challenge of lung cancer. The goal of the YSILC is to reduce mortality from lung cancer through development of novel therapeutics and treatment approaches that are based on an understanding of targetable biochemical and immunological pathways involved in progression of lung cancer, acquisition of resistance, and development of metastasis The YSILC translational research team will accomplish this objective through three projects: Project 1: Test the hypotheses that Siglec-15 (S15) is a major immune suppressor in PD-L1/B7-H1-negative lung cancer and that blockade of S15 can be efficacious for a subset of lung cancer patients; Project 2: Evaluate mechanism-based approaches to counter tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer; Project 3: Targeting lung cancer metastasis and drug resistance in the central nervous system. There are three Cores (Administrative; Biostatistics and Bioinformatics; and Biospecimen, Pathology, and Genomics) to support the projects and their clinical aims, mechanistic studies, and evaluation of biomarkers for clinical application. Strong Developmental Research and Career Enhancement Programs (DRP, CEP) with a history of choosing diverse and productive projects with good outcomes are also proposed. The highly coordinated YSILC projects, cores, and programs are focused on developing novel lung cancer therapies, with analysis of patient samples, cell-based assays, production of human cell lines and animal models of disease as a guide to design prospective trials that translate these innovative targeted approaches to clinical therapies. Each of these projects has a clinical trial (either investigator-initiated or NCI-based) designed to test the sensitivity and resistance of the new therapy with molecular correlates. The expected translational outcomes of the program include: (1) a highly coordinated and focused development of a novel immune agent discovered during our current SPORE research; (2) an improved understanding of genetic and epigenetic mechanisms of resistance to EGFR therapies and how to combat it; (3) an understanding of the mechanism underlying brain metastasis; (4) expanding the breadth of lung cancer research by developing the next generation of investigators and encouraging established investigators in other fields to pursue studies on lung cancer through our CEP and DRP programs.

耶鲁孢子在肺癌中的作用（silc）综述